Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a repurchase of 51,000 H shares on 13 May 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were bought on-market at prices between HK$21.82 and HK$22.22, translating to a volume-weighted average of HK$22.03 and a total consideration of HK$1.12 million. All repurchased shares have been retained as treasury stock.

Key capital changes • Opening balance on 12 May 2026: 327.20 million issued shares (excluding 9.15 million treasury shares). • Post-buyback balance on 13 May 2026: 327.15 million issued shares (excluding 9.20 million treasury shares). • The 51,000-share reduction represents 0.0152% of the company’s outstanding share count immediately before the transaction. • Total issued shares remain unchanged at 336.35 million, as repurchased shares are held in treasury.

Repurchase mandate utilisation • Shareholders approved a repurchase mandate on 13 May 2026 for up to 32.72 million shares. • To date, 51,000 shares, or 0.0152% of the authorised limit, have been executed under this mandate.

Regulatory timeline • A moratorium on issuing new shares or disposing of treasury shares is in effect until 12 June 2026, in line with Hong Kong Main Board Rule 10.06(3)(a).

The company confirmed that the transaction complied with all applicable listing rules and statutory requirements.